Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Rounds Out Zyrtec Line With Chewable Tablet NDA Approval

This article was originally published in The Tan Sheet

Executive Summary

Pfizer hopes to increase pediatric use of its Rx allergy drug Zyrtec (cetirizine) with new 5 mg and 10 mg chewable tablets formulations, to be available starting in late April and moving to full distribution in early summer
Advertisement

Related Content

Antihistamine Price Erosion Justifies Forced Switch – WellPoint
Antihistamine Price Erosion Justifies Forced Switch – WellPoint
Antihistamine Price Erosion Justifies Forced Switch – WellPoint
Pfizer’s Zyrtec Remains Strong As Rx Antihistamine Market Weakens
Pfizer’s Zyrtec Remains Strong As Rx Antihistamine Market Weakens

Topics

Advertisement
UsernamePublicRestriction

Register

PS096617

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel